17238-58-3

Usage

Primary use

Research chemical

Pharmacological properties

Interactions with neurotransmitter receptors in the central nervous system

Potential therapeutic effects

Anxiety and depression

Research focus

Development of new medications for neurological and psychiatric disorders

Current understanding

Further research needed to fully understand pharmacological properties and potential therapeutic applications

InChI:InChI=1/2C11H16N4.H2O4S/c2*12-11(13)15-8-6-14(7-9-15)10-4-2-1-3-5-10;1-5(2,3)4/h2*1-5H,6-9H2,(H3,12,13);(H2,1,2,3,4)

Upstream product

• 92-54-6 4-phenyl-1-piperazine 

Downstream Products

• 82113-96-0 4-Amino-2-(4-phenyl-piperazin-1-yl)-pyrimidine-5-carboxylic acid (3-trifluoromethyl-phenyl)-amide 

Relevant academic research and scientific papers

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I)-(XIII), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

A novel, facile methodology for the synthesis of N,N′-bis(tert-butoxycarbonyl)-protected guanidines using polymer-supported carbodiimide

A novel methodology for the synthesis of guanidines from amines has been developed using polymer assisted synthesis, potentially allowing the preparation of series of compounds in a high throughput manner. The methodology comprises the use of polymer-supported carbodiimide as the activating agent for N,N′-bis(tert-butoxycarbonyl) thiourea with polymer-supported trisamine as a scavenger, followed by deprotection with trifluoroacetic acid. For the first time, polymer-supported carbodiimide has been utilized as an activating agent to synthesize guanidines.